Dynamic path analysis - a useful tool to investigate mediation processes in clinical survival trials

被引:15
|
作者
Strohmaier, Susanne [1 ]
Roysland, Kjetil [1 ]
Hoff, Rune [1 ]
Borgan, Ornulf [2 ]
Pedersen, Terje R. [3 ]
Aalen, Odd O. [1 ]
机构
[1] Univ Oslo, Oslo Ctr Biostat & Epidemiol, Dept Biostat, N-0317 Oslo, Norway
[2] Univ Oslo, Dept Math, N-0317 Oslo, Norway
[3] Univ Oslo, Ulleval Hosp, N-0317 Oslo, Norway
关键词
additive hazard regression; directed acyclic graphs; direct effect; IDEAL study; indirect effect; mediation analysis; survival analysis; MYOCARDIAL-INFARCTION; APOLIPOPROTEIN-B; END-POINTS; CHOLESTEROL; EVENTS; RISK;
D O I
10.1002/sim.6598
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
When it comes to clinical survival trials, regulatory restrictions usually require the application of methods that solely utilize baseline covariates and the intention-to-treat principle. Thereby, much potentially useful information is lost, as collection of time-to-event data often goes hand in hand with collection of information on biomarkers and other internal time-dependent covariates. However, there are tools to incorporate information from repeated measurements in a useful manner that can help to shed more light on the underlying treatment mechanisms. We consider dynamic path analysis, a model for mediation analysis in the presence of a time-to-event outcome and time-dependent covariates to investigate direct and indirect effects in a study of different lipid-lowering treatments in patients with previous myocardial infarctions. Further, we address the question whether survival in itself may produce associations between the treatment and the mediator in dynamic path analysis and give an argument that because of linearity of the assumed additive hazard model, this is not the case. We further elaborate on our view that, when studying mediation, we are actually dealing with underlying processes rather than single variables measured only once during the study period. This becomes apparent in results from various models applied to the study of lipid-lowering treatments as well as our additionally conducted simulation study, where we clearly observe that discarding information on repeated measurements can lead to potentially erroneous conclusions. Copyright (c) 2015 John Wiley & Sons, Ltd.
引用
收藏
页码:3866 / 3887
页数:22
相关论文
共 50 条
  • [31] Objective breast symmetry analysis with the breast analyzing tool (BAT): improved tool for clinical trials
    Wilfried Krois
    Alexander Ken Romar
    Thomas Wild
    Peter Dubsky
    Ruth Exner
    Peter Panhofer
    Raimund Jakesz
    Michael Gnant
    Florian Fitzal
    Breast Cancer Research and Treatment, 2017, 164 : 421 - 427
  • [32] Objective breast symmetry analysis with the breast analyzing tool (BAT): improved tool for clinical trials
    Krois, Wilfried
    Romar, Alexander Ken
    Wild, Thomas
    Dubsky, Peter
    Exner, Ruth
    Panhofer, Peter
    Jakesz, Raimund
    Gnant, Michael
    Fitzal, Florian
    BREAST CANCER RESEARCH AND TREATMENT, 2017, 164 (02) : 421 - 427
  • [33] Propofol and survival: an updated meta-analysis of randomized clinical trials
    Kotani, Yuki
    Pruna, Alessandro
    Turi, Stefano
    Borghi, Giovanni
    Lee, Todd C. C.
    Zangrillo, Alberto
    Landoni, Giovanni
    Pasin, Laura
    CRITICAL CARE, 2023, 27 (01)
  • [34] Multiple random change points in survival analysis with applications to clinical trials
    Xu, Jianbo
    STATISTICAL PAPERS, 2024, 65 (07) : 4267 - 4298
  • [36] Propofol and survival: an updated meta-analysis of randomized clinical trials
    Yuki Kotani
    Alessandro Pruna
    Stefano Turi
    Giovanni Borghi
    Todd C. Lee
    Alberto Zangrillo
    Giovanni Landoni
    Laura Pasin
    Critical Care, 27
  • [37] Reply to “Propofol and survival: an updated meta‑analysis of randomized clinical trials”
    Manuel Alberto Guerrero Gutierrez
    José A. Meade-Aguilar
    Diego Escarraman Martinez
    Critical Care, 27
  • [38] DISCUSSION OF SESSION-1 - CLINICAL-TRIALS, SURVIVAL ANALYSIS
    FISHER, LD
    STATISTICS IN MEDICINE, 1992, 11 (14-15) : 1881 - 1885
  • [39] Analysis and Design of Clinical Trials Using Additive Hazards Survival Endpoints
    McDaniel, Lee S.
    Yu, Menggang
    Chappell, Rick
    STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2019, 11 (03): : 274 - 282
  • [40] Restricted mean survival time analysis in heart failure clinical trials
    Perego, C.
    Sbolli, M.
    Specchia, C.
    Oriecuia, C.
    Peveri, G.
    Fiuzat, M.
    O'Connor, C. M.
    Metra, M.
    Wei, L. J.
    Psotka, M. A.
    EUROPEAN HEART JOURNAL, 2020, 41 : 1039 - 1039